---
title: "ETHK Labs Reclassifies B-Soft Deal as Major Transaction After Listing Rules Review"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/278759899.md"
description: "ETHK Labs Inc. has reclassified its acquisition of B-Soft as a major transaction under Hong Kong listing rules after a review. The deal grants ETHK control over B-Soft’s board, necessitating the application of 100% of B-Soft’s assets for transaction-size tests. A reassessment revealed that the deal exceeds 25% but is below 100%, triggering stricter requirements. The board acknowledged prior non-compliance and plans to hold an extraordinary general meeting for shareholder approval to regularize the acquisition. The current analyst rating for IVD Medical Holding Limited (HK:1931) is a Hold with a price target of HK$1.50."
datetime: "2026-03-11T14:39:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278759899.md)
  - [en](https://longbridge.com/en/news/278759899.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278759899.md)
---

# ETHK Labs Reclassifies B-Soft Deal as Major Transaction After Listing Rules Review

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

IVD Medical Holding Limited ( (HK:1931) ) has provided an announcement.

ETHK Labs Inc. has clarified that its previously announced acquisition of shares and voting rights in Chinese technology company B-Soft should be treated as a major transaction under Hong Kong listing rules, rather than a discloseable transaction. Because the deal structure grants ETHK Labs control over B-Soft’s board and consolidates B-Soft’s financial results, the company must now apply 100% of the target’s assets, revenue and profit for transaction-size tests.

A reassessment in strict compliance with Rule 14.28 showed that one or more percentage ratios for the deal exceed 25% but remain below 100%, triggering the more stringent major transaction requirements. The board acknowledged earlier non-compliance with rules on issuing a circular and obtaining shareholder approval, attributing it to misinterpretation amid a complex cross-border deal, and plans to convene an extraordinary general meeting to seek shareholder ratification and regularize the acquisition and related voting-rights entrustment.

The most recent analyst rating on (HK:1931) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on IVD Medical Holding Limited stock, see the HK:1931 Stock Forecast page.

**More about IVD Medical Holding Limited**

ETHK Labs Inc., formerly known as IVD Medical Holding Limited, is a Cayman Islands–incorporated company listed in Hong Kong that has expanded from its medical and diagnostics roots into broader technology-related investments. The group is now focusing on strategic acquisitions, including gaining control over Chinese technology firm B-Soft, to deepen its presence in the digital and healthcare technology space.

**Average Trading Volume:** 4,698,216

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$1.95B

Find detailed analytics on 1931 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [01931.HK](https://longbridge.com/en/quote/01931.HK.md)

## Related News & Research

- [ETHK Labs Sets March 2026 Board Meeting to Approve 2025 Results](https://longbridge.com/en/news/278742026.md)
- [ETHK Labs Rebrands with New English Name and Stock Short Name in Hong Kong](https://longbridge.com/en/news/273715634.md)
- [CCI will not allow 'winner-takes-all tyranny' of Big Tech: Member](https://longbridge.com/en/news/287026224.md)
- [Mercury Raises $200 Million Series D at $5.2B Valuation](https://longbridge.com/en/news/287090050.md)
- [Stephens Investment Management Group LLC Increases Stock Position in PAR Technology Corporation $PAR](https://longbridge.com/en/news/286746769.md)